Measurement of Thromboxane Biosynthesis in Health and Disease

Patrono, Carlo; Rocca, Bianca

doi:10.3389/fphar.2019.01244

Cited by 66 publications

(68 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TXA2 is the major AA derivative synthesized via the COX-1 pathway [51] . TXA2 can enhance dopamine release and suppress GABAergic transmission by stimulating the TXA2 receptor TXAR2 [ 52 , 53 ].…”

Section: Discussionmentioning

confidence: 99%

Dysregulation of phospholipase and cyclooxygenase expression is involved in Schizophrenia

Yang

Jiang

et al. 2021

EBioMedicine

View full text Add to dashboard Cite

Background: Schizophrenia (SZ) is a severe mental disease with highly heterogeneous clinical manifestations and pathological mechanisms. Schizophrenia is linked to abnormalities in cell membrane phospholipids and blunting of the niacin skin flush response, but the associations between these phenotypes and its molecular pathogenesis remain unclear. This study aimed to describe the PLA2/COX pathway, the key link between phospholipids and niacin flush, and to illustrate the pathogenic mechanisms in schizophrenia that mediate the above phenotypes. Methods: A total of 166 patients with schizophrenia and 54 healthy controls were recruited in this study and assigned to a discovery set and a validation set. We assessed the mRNA levels of 19 genes related to the PLA2/COX cascade in leukocytes by real-time PCR. Plasma IL-6 levels were measured with an ELISA kit. Genetic association analysis was performed on PLA2G4A and PTGS2 to investigate their potential relationship with blunted niacin-skin response in an independent sample set. Findings: Six of the 19 genes in the PLA2/COX pathway exhibited significant differences between schizophrenia and healthy controls. The disturbance of the pathway indicates the activation of arachidonic acid (AA) hydrolysis and metabolization, resulting in the abnormalities of membrane lipid homeostasis and immune function, further increasing the risk of schizophrenia. On the other hand, the active process of AA hydrolysis from cell membrane phospholipids and decreased transcription of CREB1, COX-2 and PTGER4 may explain the reported findings of a blunted niacin response in schizophrenia. The significant genetic associations between PLA2G4A and PTGS2 with the niacin-skin responses further support the inference. Interpretation: These results suggested that the activation of AA hydrolysis and the imbalance in COX-1 and COX-2 expression are involved in the pathogenesis of schizophrenia and blunting of the niacin flush response.

show abstract

Section: Discussionmentioning

confidence: 99%

Dysregulation of phospholipase and cyclooxygenase expression is involved in Schizophrenia

Yang

Jiang

et al. 2021

EBioMedicine

View full text Add to dashboard Cite

show abstract

“…It has also been reported that high levels of glutaric acid indicates that the body may be more susceptible to hematological toxicity ( 47 ). Arachidonic acid is a polyunsaturated ω-6 fatty acid that occurs in the phospholipids of cell membranes; it is a precursor molecule during the synthesis of thromboxane A2 ( 48 ). Arachidonic acid generates thromboxane A2 through the thromboxane pathway to cause platelet aggregation, which triggers various cardiovascular diseases ( 49 ).…”

Section: Discussionmentioning

confidence: 99%

Analysis of biomarkers and metabolic pathways in patients with unstable angina based on ultra‑high‑performance liquid chromatography‑quadrupole time‑of‑flight mass spectrometry

Liu

Zhang

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

unstable angina (ua) is a coronary disease with a high mortality and morbidity worldwide. The present study aimed to use non-invasive techniques to identify urine biomarkers in patients with ua, so as to provide more information for the early diagnosis and treatment of the disease. Based on metabolomics, urine samples from 28 patients with ua and 28 healthy controls (Hcs) were analyzed using ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (uPlc-Q-ToF/MS). a total of 16 significant biomarkers that could distinguish between patients with ua and Hcs, including d-glucuronic acid, creatinine, succinic acid and n-acetylneuraminic acid, were identified. The major metabolic pathways associated with ua were subsequently analyzed by non-targeted metabolomics. The results demonstrated that amino acid and energy metabolism, fatty acid metabolism, purine metabolism and steroid hormone biosynthetic metabolism may serve important roles in ua. The results of the current study may provide a theoretical basis for the early diagnosis of ua and novel treatment strategies for clinicians. The trial was registered with the chinese clinical Trial registration Center (registration no. ChiCTR-ROC-17013957) at Tianjin university of Traditional chinese Medicine.

show abstract

“…11-DH-TXB 2 is the metabolite of TXB 2 , and the plasma level of 11-DH-TXB 2 has been suggested to be an indicator of TXA 2 production in humans. 18 – 20 Aspirin activity and antiplatelet action can be evaluated by measurement of the end-products of the TXA 2 pathway, such as 11-DH-TXB 2 . The 11-DH-TXB 2 levels also reflect the amount of TXA 2 derived from other sources besides platelets, such as macrophages and monocytes.…”

Section: Discussionmentioning

confidence: 99%

Immature platelets and antiplatelet therapy response to aspirin in Kawasaki disease

Che

Long

et al. 2018

DDDT

View full text Add to dashboard Cite

IntroductionKawasaki disease is a kind of systemic vasculitis that mainly damages moderate and small-sized blood vessels, and is a leading cause of coronary artery lesions (CAL). Antiplatelet therapy is a routine component of Kawasaki disease treatment strategies. So it is important to evaluate the antiplatelet effect of aspirin because of the individual biological variability of antiplatelet effect of aspirin. The immature platelet fraction (IPF) has attracted particular attention as it may influence the antiplatelet effect of aspirin. This study investigated the prognostic factors for evaluating the degree of vasculitis and the effect of antiplatelet therapy in children with Kawasaki disease.Materials and methodsBlood samples were collected from 44 patients with Kawasaki disease before aspirin treatment and 7 to 10 days after treatment. The IPF counts, percentage of the IPF, and highly fluorescent IPF were detected by a Sysmex XE-5000 instrument. The levels of 11-dehydrothromboxane B2 (11-DH-TXB2), soluble CD40 ligand (sCD40L), and soluble P-selectin (sP-selectin) were measured by ELISA. The correlation between the measured factors and the degree of coronary artery damage in Kawasaki disease was analyzed.ResultsWe found that 11-DH-TXB2, sP-selectin, and sCD40L levels were much more elevated in the CAL group than in the non-coronary artery lesions (NCAL) group before aspirin treatment. The concentrations of 11-DH-TXB2, sCD40L, sP-selectin, and IPF were reduced after aspirin treatment in the NCAL group but not the CAL group. This is related to the degree of coronary artery damage in Kawasaki disease patients. Additionally, 11-DH-TXB2, sCD40L, sP-selectin, and IPF were positively correlated with the degree of coronary artery damage in Kawasaki disease patients.ConclusionThe current study suggests that the presence of high plasma concentrations of 11-DH-TXB2, sCD40L, sP-selectin, and IPF can be considered a risk factor and experimental biomarker for CAL in Kawasaki disease patients.

show abstract

Measurement of Thromboxane Biosynthesis in Health and Disease

Cited by 66 publications

References 88 publications

Dysregulation of phospholipase and cyclooxygenase expression is involved in Schizophrenia

Dysregulation of phospholipase and cyclooxygenase expression is involved in Schizophrenia

Analysis of biomarkers and metabolic pathways in patients with unstable angina based on ultra‑high‑performance liquid chromatography‑quadrupole time‑of‑flight mass spectrometry

Immature platelets and antiplatelet therapy response to aspirin in Kawasaki disease

Contact Info

Product

Resources

About